ZIOPHARM Oncology (NASDAQ: ZIOP) recently received a number of ratings updates from brokerages and research firms:

  • 11/17/2018 – ZIOPHARM Oncology was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 11/15/2018 – ZIOPHARM Oncology was upgraded by analysts at Raymond James from a “market perform” rating to an “outperform” rating. They now have a $5.00 price target on the stock.
  • 11/13/2018 – ZIOPHARM Oncology was given a new $6.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 11/3/2018 – ZIOPHARM Oncology was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.

ZIOP stock opened at $3.20 on Monday. ZIOPHARM Oncology Inc. has a twelve month low of $1.90 and a twelve month high of $5.24. The company has a market cap of $455.62 million, a PE ratio of -6.04 and a beta of 1.85.

Several hedge funds have recently added to or reduced their stakes in ZIOP. BlackRock Inc. grew its position in shares of ZIOPHARM Oncology by 8.5% during the second quarter. BlackRock Inc. now owns 9,167,740 shares of the biotechnology company’s stock worth $27,686,000 after buying an additional 717,804 shares in the last quarter. FMR LLC acquired a new stake in shares of ZIOPHARM Oncology during the third quarter worth approximately $1,647,000. Bank of America Corp DE grew its position in shares of ZIOPHARM Oncology by 198.1% during the second quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock worth $301,000 after buying an additional 201,063 shares in the last quarter. Vident Investment Advisory LLC grew its position in shares of ZIOPHARM Oncology by 46.8% during the second quarter. Vident Investment Advisory LLC now owns 587,255 shares of the biotechnology company’s stock worth $1,774,000 after buying an additional 187,195 shares in the last quarter. Finally, Private Advisor Group LLC acquired a new stake in shares of ZIOPHARM Oncology during the third quarter worth approximately $372,000. 39.19% of the stock is owned by institutional investors and hedge funds.

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.